Apellis Pharmaceuticals Names New Chief Medical Officer
Ticker: APLS · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1492422
Sentiment: neutral
Topics: executive-change, personnel
Related Tickers: APLS
TL;DR
Apellis CMO out, new CMO in. Lohmann takes the reins.
AI Summary
Apellis Pharmaceuticals, Inc. announced on January 8, 2025, the departure of its Chief Medical Officer, Dr. Federico Cervera, effective January 10, 2025. The company also announced the appointment of Dr. Caroline Lohmann as the new Chief Medical Officer. Dr. Lohmann previously served as Executive Vice President and Head of Global Medical Affairs at Apellis.
Why It Matters
A change in leadership for a key executive role like Chief Medical Officer can impact the company's strategic direction and execution of its drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions can signal internal shifts or challenges, potentially affecting operational continuity and strategic execution.
Key Players & Entities
- Apellis Pharmaceuticals, Inc. (company) — Registrant
- Dr. Federico Cervera (person) — Departing Chief Medical Officer
- Dr. Caroline Lohmann (person) — Appointed Chief Medical Officer
- January 8, 2025 (date) — Date of Report
- January 10, 2025 (date) — Effective date of departure
FAQ
Who is the new Chief Medical Officer at Apellis Pharmaceuticals?
Dr. Caroline Lohmann has been appointed as the new Chief Medical Officer.
When is Dr. Federico Cervera's departure effective?
Dr. Federico Cervera's departure is effective January 10, 2025.
What was Dr. Caroline Lohmann's previous role at Apellis?
Dr. Caroline Lohmann previously served as Executive Vice President and Head of Global Medical Affairs at Apellis.
What is the date of this 8-K filing?
The date of the report is January 8, 2025.
What are the main items reported in this 8-K filing?
This 8-K filing reports on Results of Operations and Financial Condition, Departure of Directors or Certain Officers, Election of Directors, Appointment of Certain Officers, and Financial Statements and Exhibits.
Filing Stats: 1,531 words · 6 min read · ~5 pages · Grade level 11.1 · Accepted 2025-01-13 09:08:24
Key Financial Figures
- $33.00 — mon stock at an exercise price equal to $33.00 per share, the closing price of the Com
Filing Documents
- d885806d8k.htm (8-K) — 33KB
- d885806dex991.htm (EX-99.1) — 49KB
- g885806g33r93.jpg (GRAPHIC) — 2KB
- 0001193125-25-005052.txt ( ) — 217KB
- apls-20250108.xsd (EX-101.SCH) — 3KB
- apls-20250108_lab.xml (EX-101.LAB) — 17KB
- apls-20250108_pre.xml (EX-101.PRE) — 11KB
- d885806d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apellis Pharmaceuticals, Inc. Date: January 13, 2025 By: /s/ Timothy Sullivan Timothy Sullivan Chief Financial Officer